Literature DB >> 8655206

Pharmacokinetics of azithromycin in normal and impaired renal function.

D Höffler1, P Koeppe, B Paeske.   

Abstract

Plasma and urine levels of 12 healthy subjects and 30 patients with renal insufficiency of different degrees were examined after oral administration of four 250 mg capsules azithromycin (total daily dose 1,000 mg). The concentrations were determined by cup plate method. The pharmacokinetic parameters were determined model-dependent and noncompartmentally. Neither the area under the plasma concentration curve nor the distribution volume in steady state (16 l/kg body weight) nor the maximal plasma concentration were significantly affected by renal insufficiency. Thus the dosage regimen of azithromycin in renal impairment may (and should) be the same as in patients with normal renal function. The nonrenal clearance is not affected by renal insufficiency, but the concentration of the substance in the tubular lumen (the "tubular load") may be increased.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8655206     DOI: 10.1007/bf01713565

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  5 in total

1.  Giant inverted T waves and substantial QT interval prolongation induced by azithromycin in an elderly woman with renal insufficiency.

Authors:  Tongtong Yu; Tiesheng Niu
Journal:  Can Fam Physician       Date:  2014-11       Impact factor: 3.275

Review 2.  Azithromycin. A review of its use in paediatric infectious diseases.

Authors:  H D Langtry; J A Balfour
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

3.  Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors.

Authors:  Anna Kezerashvili; Himad Khattak; Aron Barsky; Reza Nazari; John D Fisher
Journal:  J Interv Card Electrophysiol       Date:  2007-06-02       Impact factor: 1.900

4.  Comparison of gastrointestinal side effects from different doses of azithromycin for the treatment of gonorrhoea.

Authors:  Jason J Ong; Ivette Aguirre; Magnus Unemo; Fabian Y S Kong; Christopher K Fairley; Jane S Hocking; Eric P F Chow; Warittha Tieosapjaroen; Jenny Ly; Marcus Y Chen
Journal:  J Antimicrob Chemother       Date:  2022-06-29       Impact factor: 5.758

5.  Pharmacokinetics under the COVID-19 storm.

Authors:  Venkatesh Pilla Reddy; Eman El-Khateeb; Heeseung Jo; Natalie Giovino; Emily Lythgoe; Shringi Sharma; Weifeng Tang; Masoud Jamei; Amin Rastomi-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2020-11-23       Impact factor: 3.716

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.